Boehringer Ingelheim and Cue Biopharma announced a strategic research collaboration and license agreement, receiving FDA feedback on a Pre-IND Briefing Document.

The entities involved

• Boehringer Ingelheim →

  German pharmaceutical company

  • Sheila Denton was appointed as General Counsel & Corporate Secretary at Boehringer Ingelheim.Mon 15:03
  • Boehringer Ingelheim and Palatin Technologies reported $13.2 million in revenue from their Fiscal 2026 collaboration.Mon 13:31
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

• FDA approval enables commercial opportunity involving CBRE Group.Sep 17
• Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.Aug 31
• FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.Aug 28
• A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.Sep 2
• Collaboration revenue from GSK increased total revenue, and FDA action is needed for tepipenem HBR approval.Jun 7